Tisotumab vedotin (HuMax-TF-ADC)

DRUG2 trials

Sponsors

Seagen Inc.

Conditions

Bladder CancerCervix CancerEndometrium CancerEsophagus CancerLung Cancer (NSCLC)Lung Cancer(NSCLC)Ovary CancerProstate Cancer (CRPC)

Phase 1

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

CompletedNCT02001623

Seagen Inc.Bladder Cancer, Cervix Cancer, Endometrium Cancer +5

Start: 2013-11-30End: 2019-05-02Updated: 2021-12-29

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

CompletedNCT02552121

Seagen Inc.Bladder Cancer, Cervix Cancer, Endometrium Cancer +4

Start: 2015-11-30End: 2017-12-13Updated: 2021-04-08

Related Papers

Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotin.

2025-10-03

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Clinical Cancer Research2019-12-03122 citations

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.

2019-02-08169 citations

A phase IIa study of tisotumab vedotin in patients with previously treated recurrent or metastatic cervical cancer: Updated analysis of full cervical expansion cohort

Annals of Oncology2018-10-011 citations

A single arm, phase 2, multicenter, international trial of tisotumab vedotin (HuMax-TF-ADC) in previously treated, recurrent or metastatic cervical cancer.

Journal of Clinical Oncology2018-05-201 citations

A phase I, first-in-human study to evaluate the tolerability, pharmacokinetics and preliminary efficacy of HuMax-tissue factor-ADC (TF-ADC) in patients with solid tumors.

Journal of Clinical Oncology2015-05-207 citations